Drug intelligence / Profile preview

VITAMAC

Development stage: Unknown
Lead developer: Medical University of Vienna
Administration: Oral

Overview

VITAMAC is an antioxidant nutraceutical formulation developed by the Medical University of Vienna to investigate the effects of oxidative stress on retinal hemodynamics. It consists of a specific combination of vitamins, minerals, and botanical extracts, including lutein, zeaxanthin, vitamin C, vitamin E, zinc, copper, selenium, Ginkgo biloba, flavonoids, fish oil, and alpha-lipoic acid. The supplement is designed to scavenge reactive oxygen species (ROS) and has been studied in randomized, placebo-controlled trials using an endotoxin (LPS)-induced systemic inflammation model in healthy humans to determine its impact on retinal vascular reactivity and systemic inflammatory responses.

Brand names: VITAMAC
Other names: Vitamin and mineral supplementAntioxidant food supplement

Beyond the preview

Go deeper on VITAMAC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VITAMAC.

Explore the full profile